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Although initial success rates for coronary angioplasty
have improved, the rate of restenosis within 6 months
of the procedure has persisted at 30 to 40%. The relation
of restenosis to initial success, recurrence of symptoms
and risk factors suggests that high grade or total lesions,
long lesions, lesions in the proximal left anterior de-
scending artery or in saphenous grafts, and the absence
of intimal dissection after angioplasty are associated with
an increased risk of restenosis. Unstable angina, male
sex and diabetes are clinical factors associated with a
greater risk of restenosis. Pathologic specimens suggest
that plaque splitting and disruption are found acutely
after angioplasty, but that restenosis occurs as an ex-
Percutaneous transluminal coronary angioplasty is an es-
tablished technique capable of providing immediate relief
of symptoms in patients with angina pectoris (1-5) and of
restoring blood flow in acute myocardial infarction (6-9).
Although continuing improvements have occurred in an-
gioplasty technique, success rate and application to a wider
patient population (4,10, II), the problem of restenosis after
the procedure has proved enduring and formidable. Alter-
native methods to relieve coronary stenoses continue to be
developed, but the widespread use of such new technologies
is not anticipated for several years. Therefore, there is a
strong rationale for assessing aggressive medical therapy
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cessivereparative, proliferative response of smooth mus-
cle cells leading to recurrent luminal narrowing.
A prospective analysis of therapeutic interventions to
prevent restenosis, such as adminlstrating antiplatelet
and lipid-lowering agents, intensive diabetic therapy and
administration of calcium antagonists, is proposed.
Problems with timing of studies, design and sample size
are considered. Current recommendations for antires-
tenosis therapy include anti platelet therapy before and
after angioplasty, administration of heparin in some pa-
tients and intensive risk factor intervention for the 6
months after the procedure,
(J Am Coil CardioI1987;9:834-48)
that could reduce restenosis after angioplasty. The purpose
of this review will be to describe the incidence, patho-
physiology and clinical setting of restenosis, and to evaluate
therapeutic interventions that might improve the long-term
success rate of the procedure.
Clinical Restenosis
Definition of restenosis. Any definition of restenosis is
inextricably linked to the definition of initial success of
angioplasty. Reductions in diameter stenosis of >20% or
2:40% have been used to define initial success (2,12-14):
Restenosis has been defined angiographically in most studies
as a loss of initial gain in luminal diameter of 2:50%, a
2:30% increase in postangioplasty diameter stenosis, an in-
crease from <50% to 2:70% diameter stenosis, a return to
s; 10% of preangioplasty diameter stenosis or a diameter
stenosis of 2:50% at follow-up angiography (12,15). In a
majority of these studies, definitions of both initial success
and restenosis suffer from a reliance on the subjective visual
estimation of vessel diameter. High interobserver variabil-
ity, difficult edge definition on the postangioplasty film due
to irregularity and overall poor correlation with physiologic
measurements or area computations suggest that percent
diameter stenosis estimates are an inadequate variable on
0735-10971871$3.50
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Figure l. Relation between symptoms and restenosis rate. Data
from the National Heart. Lung. and Blood Institute PTCA Regis-
try. (Reprinted with permission from Holmes DR Jr. et al. 11 21. )
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from those of the NHLBI. Finally. Zaidi et al. (31) studied
184 consecutive patients. of whom 48% had angiographic
restenosis. One-third of the group with continued angio-
graphic success and two-thirds of the group with restenosis
had chest pain. Thus. estimates of restenosis rates in asymp-
tomatic individuals vary from 4% to 17% and in sympto-
matic individuals from 50% to 76%. The variability may
be due to the small sample sizes. lack of consecutive patient
series and differing definitions.
The relatively few consecutive patient series. mostly re-
ported in preliminary form. in general corroborate the NHLBI
and French Registry data. Powelson et al. (40) described a
10% restenosis rate (7 of 70 vessels) 2 days after angio-
plasty, and associated its presence at this early time with
angiographic intimaldisruption. In two seriesof 100 patients
the 30 and 60 day postangioplasty restenosis rates were 13
and 18°k). respectively (15). With usual median or mean
angiographic follow-up times of 6 months, restenosis was
reported by Dangoisse et al. (24) in 30% of 103 patients.
by Jutzy et al. (23) in 47% of 34 patients and by Levine et
al. (25) in 40% of 92 patients. Fleck et al. (22), using a
percent area stenosis rather than diameter stenosis definition.
reported a 42 % restenosis rate in 51 patients.
Implications of restenosis. The NHLBI Registry (1 2.13)
reported that 52% of patients with initially successful an-
gioplasty were event free and asymptomatic at a mean of
18 months after the procedure. Event-free survival rates
were 79 .7% for women and 69.0% for men during this
period. Together with the initial success rate of only 60 .3%
in womenand 66.2% in men. the Registry data (13) indicate
a substantial difference in the long-term success rate of
angioplasty from that achieved by alternate formsof therapy
such as coronary artery bypass grafting, which carries a
much higher 18 month symptom-free rate (41,42). These
results reflect the experience obtained 3 to 5 years before
the time of this writing; initial angioplasty success rates
have improved significantly in the interim(4.10,11). A ran-
which to base definitions of success or restenosis. Although
evaluation of diameter stenosis estimates has yielded broadly
useful information about coronary stenoses, use of at least
two orthogonal projections or quantitative angiographic or
videodensitometricmeasurements have proven more precise
and should be considered methods of choice for assessing
initial success and restenosis (16-21) . Percent increases or
decreases in area or contrast density will continue to be
selected arbitrarily, but the methods and calculations used
must be stated in detail until standard definitions can be
established.
Incidence of restenosis. The true incidence of restenosis
after coronary angioplastycan only be assessed from studies
involving the relatively few consecutive patients who have
been restudied at a predetermined interval after successful
angioplasty. Such studies have demonstrated that approxi-
mately 30 to 40 % of patients develop restenosis within the
first 6 to 12 months (22- 25) . This incidence approximates
the frequency of restenosis assessed in the National Heart,
Lung. and Blood Institute (NHLBI) Registry (1 2) in which
initial successful angioplasty was achieved in 70% of 3.079
patients. Of 665 patients from the participating centers that
had at least 74% angiographic follow-up (median = 84%),
34% demonstrated restenosis a median of 6.3 months after
angioplasty. In the FrenchPercutaneous TransluminalCoro-
nary Angioplasty registry (26). a 73 to 78% initial success
rate was reported in 3.198 patients. Restenosis rates were
31% for the 2,385 patients with single vessel disease and
34% for those with multivessel disease. The percent of
patients who had angiographic follow-up was not reported.
Similar restenosis rates have been noted in other series
( 14,27-39) .
Problems with restenosis studies. In most series, the
timing of many restudies has been dictated by symptomatic
status. Patients with recurrent chest pain have proceeded to
repeat angiography earlier than asymptomatic patients. The
incidence of restenosis in the NHLBI Registry (12) was
highest within the first 5 months after angioplasty when
81% of patients studied were symptomatic, compared with
a 38% symptomatic rate among those who were studied
more than 5 months after angioplasty. In patients who had
definite or probable angina, restenosis was present in 56%
compared with 14% of asymptomatic patients. In otherwords.
of all patients with restenosis 20% were without symptoms
(Fig. I). Levine et al. (25), while documenting an overall
restenosis rate of 40%, reported a considerably lower in-
cidence of restenosis in asymptomatic patients (4 .3%) whereas
the incidence among symptomatic patients was signifi cantly
higher (76%). Lack of a clear relation between angiographic
restenosis and symptoms was suggested by Mabin et al.
(14); in 84 patients. 71% of symptomatic and 14% of asymp-
tomatic patients had restenosis, a 32% overall rate. Defi-
nitions of initial success ( ~40% reduction of diameter) and
restenosis (increase in stenosis of ~30% ) were different
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Lesion-related factors. Totally occluded vessels (49-5 1)
or lesions with < 90% diameter stenosis (34, 35) or high
initial translesional gradient ( 12) are more frequently noted
to show angiographic restenosis than lesions < 90% or with
a lesser gradient. Also. longer lesions are more prone to
rcstenosis than shorter ones, with a dramatic increase in
restenosis rate for lesions longer than 15 mm (52). Lesions
in the left main coronary artery (53) or the proximal left
anterior descending artery (34,35.39), especially near bi-
furcations (33), have been reported to have a higher reste-
nosis rate than more distal lesions or right coronary or cir-
cumflex artery lesions. There is controversy surrounding the
rcstenosis rate of lesions subjected to angioplasty for a sec-
ond time. Restenosis rates slightly less than (54), equal to
(24,28) or slightly greater than (55) rates after initial an-
gioplasty havebeen reported. Restenosis rates in angioplasty
of saphenous vein bypass grafts are greater than in native
vessels (12.56- 59). Consistent lesion-related factors appear
to be proximal left coronary artery disease. high grade initial
stenosis. long lesions and bypass grafts.
Procedure-related factors. The presence of an intimal
crack or dissection. assessed angiographically, was asso-
ciated with a greater incidence of early complications such
as acute reocclusion (4,60) or restenosis 48 hours after an-
gioplasty (40). However, dissection appears to convey some
protection against restenosis in the later period after angio-
plasty when compared with lesions without this angio-
left circumflex. RCA
dornized trial comparing the two procedures has been pro-
posed (43).
The occurrence of symptoms within the first 18 months
after successful angioplasty does not directly imply that the
cause of symptoms was restenosis in all patients because
progression of coronary disease at an alternate site. devel-
opment of coronary spasm at the site of angioplasty or chest
pain of noncardiac origin may be responsible. Nevertheless,
restenosis accounts for most symptoms recurring within 6
months after angioplasty.
Joelson et al. (44) performed angiography on 77 con-
secutive patients with postangioplasty chest pain. Forty-
three of these had restenosis, and all but two presented with
chest pain within 6 months of angioplasty. Fifteen patients
presented with progressive coronary disease distant from
the angioplasty site, and all but two presented with symp-
toms more than 6 months after angioplasty. Robert et al.
(45), in a similar study, detected restenosis in 74 and 28%
of patients presenting with chest pain < 6 and > 6 months
after angioplasty, respectively. Forty percent of the group
presenting 6 months after angioplasty had progression of
coronarydisease elsewhere. Finally. Levine et al. (25) found
that of 25 1 patients followed up for a mean of 21 months,
43% became symptomatic. Repeat angiography revealed
restenosis in 67%. progression of disease elsewhere in 13%
and no anatomic explanation for symptoms in 19%. The
last group may have suffered fromcoronary spasm. although
such a diagnosis is speculative.
Because most cases of restenosis occur within the first 6
months aft er angioplasty, is it possible to screen f or the
occurrence of restenosis by noninvasive means shortly after
the procedure? Wijns et al. (46) reported that an abnormal
thallium reperfusion scan in asymptomatic patients 4 weeks
after angioplasty could predict the recurrence of stenosis in
74% of patients in whom it later occurred. This test was
considerably betterthan the exercise electrocardiogram which,
when abnormal, had a predictive accuracy of 50% for re-
stenosis. Similar findings were reported by Stuckey et al.
(47). DePuey et al. (48) reported that exercise gated radio-
nuclide ventriculography within 4 days of angioplasty. when
abnormal, had a predictive accuracy of 73% for restenosis.
Such findings suggest that hemodynamic abnormalities that
ultimately will probably produce symptoms and angio-
graphic evidence of restenosis are manifested within a few
weeks after angioplasty. However, suffic ient accuracy of
noninvasive testing has not been demonstrated to replace
follow-up angiography in the detection of restenosis.
Risk Factors for Restenosis
Some studies have attempted to identify specific clinical
or technical considerations that predispose to coronary an-
gioplasty restenosis, These are summarized in Table I and
fall into three main groups.
Table L Risk Factors forCoronary Restenosis
After Angioplasty
Risk Factors
Lesion-related
Severity
Total occlusions
> 90% Stenosis
Site
Left main artery
LAD > RCA > LCx
Bifurcation site
Saphenous graft
Prior angioplasty .)
Length > 10 to 15 mm
Procedure-related
No dissection
> 30% Residual stenosis
> 15 mm Hg residual gradient
Patient-related
Unstable angina
Male sex
Diabetes
Variant angina
Multivessel disease
Smoking
Ilyperchoiesterolemia
LAD = left anterior descending. Le x
right coronary aneries.
References
49 to 51
12.34.35
53
34.35 .39
33
12.56 to 59
55
52
17,35
12.35.61
12.29.34
12.24,34.62.67
13
35.62.66
24.64.65
37.39
62
62.68
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graphic finding, especially if associated with a low post-
angioplasty transluminal pressure gradient (17,35).
Patients with residual stenosis of < 30% immediately after
dilation are less likely to experience restenosis than those
with residual stenosis > 30% (12,35,61). A translesional
pressure gradient of < 15 to 20 mm Hg after dilation is
associated with a lower frequency of restenosis than are
gradients > 15 to 20 mm Hg (12,29,34). Increasing number
of dilations (24,51), higher maximal balloon inflation pres-
sure (29,51,62) and lower balloon to artery diameter ratio
(39) were reported to be associated with restenosis, although
their importance has not been corroborated in other studies
(12,24,63).
Patient factors. Although studies thus far have involved
small numbers, Prinzmetal's variant angina (24,64.65) and
diabetes mellitus (35.62,66) may predispose to restenosis.
Other larger studies (12.24,34,62,67) have shown a positive
correlation between recent onset or unstable angina and
restenosis. Men are more prone to restenosis than are women
(13). One reason for this may be that intimal dissection
occurs with greater frequency in women than in men (13.17).
Advancing age was not associated with an increased rate of
restenosis (36). A preliminary report (68) suggested that
restenosis was associated with hyperlipidemia types Ila, lIb
and IV. Shaw et al. (62) studied multiple vessel angioplasty
and analyzed patient factors that predisposed to restenosis
in all dilated segments. Patients in whom restenosis occurred
in all lesions dilated were more likely to smoke. have a
higher cholesterol level, have diabetes and have a shorter
duration of angina than patients in whom one or some. but
not all lesions showed restenosis.
Multivessel angioplasty is associated with an increased
risk of restenosis per patient, although it is associated with
only a slightly greater clinical recurrence rate than single
vessel angioplasty. Restenosis rates may be higher with
multilesion single vessel angioplasty than multivessel an-
gioplasty (37-39,69,70).
Pathogenesis of Restenosis
Mechanism of coronary angioplasty. Pathologic find-
ings of balloon angioplasty in animals and in some human
specimens have shown denudation of endothelium, platelet
adhesion, fibrin deposition and variable degrees of disrup-
tion of elastic and medial layers (71-84) . Postmortem di-
lation of human coronary arteries and autopsy specimens of
patients who have undergone angioplasty in life but who
died in the first few days after the procedure has documented
that in humans angioplasty produces splitting of intimal
plaque, separating plaque edges, partially or completely
disrupting the media and stretching the adventitial layer
(72,76,79-81,83-85) . These findings suggest that plaque
disruption, separation, and pseudoaneurysm formation are
the mechanisms by which luminal cross-sectional area is
increased during angioplasty in humans. Examples in Figure
2 in the human femoral artery and human coronary artery
display many of these features.
Animal studies. The healing after the injury of balloon
angioplasty may be related to the pathogenesisof restenosis.
Atherosclerotic plaques have been produced with injury and
cholesterol feeding in swine, primates and rabbits (86--95).
An animal model designed to study restenosis requires
preexisting atherosclerotic vascular stenosis that can be di-
lated by balloon angioplasty. In induced rabbit aortoiliac
atherosclerosis angioplasty produced denudation of endo-
thelial cells. platelet and fibrin deposition and disruption
and splitting of atheromatous plaque (73.74,78,96,97). An-
gioplasty of such lesions in rabbits, with continuation of a
high cholesterol diet, led to restenosis within 4 weeks(96,97).
Pathologic analysis of the restenotic segment showed a layer
of lipid-laden smooth muscle cells and foam cells overlying
an acellular. split fibrous plaque (Fig. 3).
Human studies. The few coronary arteries of patients
who have undergone angioplasty and died provide evidence
to suggest mechanisms of healing and to allow a postulation
of the mechanism of restenosis. A review of previous reports
and published pathologic specimens (72.76,79,83,84,98-101)
is consistent with the view that specimens obtained during
the healing phase after angioplasty show a uniform prolif-
eration of smooth muscle cells in the intima of the artery.
Pathologic findings weeks to months after angioplasty are
summarized in Table 2 and some published micrographs are
reproduced in Figure 4. In virtually every case, it was pos-
sible to discern an outer acellular layer of the arterial wall.
often with curled-in crescentic edges. resembling the edges
of the atherosclerotic plaque split acutely as demonstrated
in humanand animal studies describing the acute mechanism
of angioplasty. In addition to this acellular layer there is a
cellular layer consisting of fibroblasts and smooth muscle
cells that extends from beneath the curled edges of the
acellular layer into the luminal space and around the inner
circumference of the vessel. These specimens suggest that
the injury inflicted by balloon dilation induced a reparative
and proliferative response which, in some cases, became
exuberant enough to encroach on the residual lumen of the
angioplasty site and to produce clinical restenosis. Most
importantly. they differ fromchronic atherosclerotic lesions
which have specializedand probablysenescent smooth mus-
cle cells in layers of basement membrane, under which
appear macrophages and areas of necrotic acellular debris
that may include cholesterol crystals and calcium (95).
Experimental Endovascular Injury
Response to injury. Intraarterial balloon injury in Ma-
caca nemestrina monkeys (86) was accompanied by loss of
endothelium at the site of injury, platelet adhesion and de-
granulation and measurable decreases in platelet survival
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Figure 2. Undilated (A) and dilated (B)
segments of human superficial femoral ar-
lery before and after angioplasty. The di- fi\
lated segment demonstrates separation of ~
plaque from the media and medial rupture.
C, Dilated human left anterior descending
coronary artery after angioplasty witha dis-
section through the outer media (0) and
plaquesplitting (S). L = lumen. (Reprinted
with permission from (A and B) ZarinsCL.
et al. I72J and (C) Block Pc. er al. 1811.)
time. At 5 to 7 days after injury smooth muscle cells were
noted in fenestrae in the internal elastic lamina. It was sug-
gested that these modified smooth muscle cells migrated in
response to intimal injury from the medial layers to a sub-
intimal location. Three months after balloon injury 5 to 15
layers of smooth muscle cells were present in the subintima
and stains demonstrated increases in collagen. elastin and
proteoglycans. Increased tritiated thymidine incorporation
was also noted in the subintimal layer suggesting active
proliferation of these cells. By 6 months after injury. this
thickened subintimal layer of smooth muscle cells had re-
gressed to one to two layers of cells (Fig. 5) (86). These
data suggest that the proliferative responseof smooth muscle
cells. with the animals on a diet not supplemented with
excess cholesterol and in the absence of further injury. was
a reversible process.
Platelets and platelet factors. The discovery of platelet-
derived growth factor, a potent mitogen and chemoattractant
and the ability to assess the effects of growth factors on
smooth muscle and endothelial cells in culture have given
new insights into factors that promote growth of these cells
(91.92.95). For example. while serum containing platelets
from whole blood, a rich source of platelet-derived growth
factor. promotes more vigorous growth of smooth muscle
cells than platelet-poor serum. it has also been discovered
(102) that lowdensity lipoprotein cholesterol promotes growth
lACC Vol. 9. No.4
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Figure 3. Top, Acutely balloon-dilated iliac artery from choles-
terol-fed rabbit showing intimal plaque fracture and dissection .
Bottom, Four weeks after dilation: with continued cholesterol
feeding restenosis has occurred with foam cells and cellular con-
nective tissue . Fractured ends of the initially dilated plaque are
evident (arrows). (Reprinted bypermissionofthe American Heart
Association Inc .. from Faxon DP. et al. [97J.)
of cultured smooth muscle cells even in platelet-free serum.
Furthermore. platelet-derived growth factor acts to increase
low density lipoprotein (103) and decrease high density
lipoprotein binding to smooth muscle cell receptors ( \04).
suggesting a synergism betweenplatelet-derivedgrowth fac-
tor and low density lipoprotein cholesterol in incorporating
new cholesterol into the cells for purposes of membrane
synthesis. Diminished high density lipoproteinbinding may
be viewed as a retardation of a process designed to carry
cholesterol away from proliferating cells. In vivo hyper-
cholesterolemiadid not delay reendothelialization of injured
arteries in an experimental preparation (105). However. en-
hancement of macrophage adhesion and increased numbers
of smooth muscle cells in the healing arterial wall were
noted (Fig. 6). It is tempting to speculate that macrophage-
derived growth factor. identified but not yet fully charac-
terized (106). may playa role in this response.
Problems with animal studies. Animal models of vas-
cular injury and known factors affecting cellular prolifera-
tion and healing after injury have been discussed in the
context of coronary angioplasty. Whether these models re-
semble the condition of human atherosclerosis in which
clinical angioplasty is employed remains debatable. As noted .
animal models use 2% cholesterol feeding that overwhelms
the exogenous cholesterol metabolism, induces excessive
lipid incorporation into reticuloendothelial cells and produces
within approximately 3 months a patternof plaque formation
that dominates small vessels and differs greatly in distri-
bution and morphology from atherosclerosis in humans. The
Watanabe hereditary hyperlipidemic rabbit (107,108) in its
homozygous state lacks liver and fihroblast receptors for
low density lipoprotein cholesterol, a defect similar to that
seen in humans with type lla hyperlipidemia. This animal.
while ingestinga diet of normal rabbit chow. develops pre-
mature atherosclerosis with a predisposition for plaque for-
mation at branch sites in the arterial tree and coronary ar-
Table 2. Studies With Published Micrographs of Coronary Arteries 17 to 330 Days
After Angioplasty
First No. of Time after PTCA
Author Ref. Year Patients (days) Findings
Hollman (132) 1983 I 65 Intimal SMC proliferation
Essed (9K) \983 \ l}O Intimal SMC proliferation
Waller (99) 1983 3 KO.90. 150 Intimal SMC proliferation
Waller (76) 1984 2 2lL 60 Fibrous proliferation +
(SVBGl cholesterol
Austin (1om 1985 2 17. 64 Intimal SMC proliferation
Colavita (83) 1986 2 49. 330 One thrombosis and one
Ca~' plaque
Ca' + = calcified; PTCA == percutaneous transluminal coronary angioplasty: SMC = smooth muscle cell:
SVBG = saphenous vein bypass grafts.
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Figure 4. Postangioplasty micrographs from four patients. A, Left anterior
descending coronary artery 90 days after angioplasty. B, Left anterior
descending coronary artery 150 days after angioplasty. C, Left anterior
descending coronary artery 90 days after angioplasty. Plaque separation
(thin arrows) and an area of complete medial interruption (triangle) are
seen in addition to fibrocellular smooth muscle cell growth adjacent to the
lumen. D, Left anterior descending artery 62 days after angioplasty (top
panel), Fractured edges of the original plaque are noted (bottom panel).
I = inner layer of smooth muscle cells; 0 = outer, hypocellular layer.
(Reprinted with permission from (A) and (B) Waller BF, et al. [99]; (C)
Essed CE, et al. [98]; and (D) Austin GE, et al. [100].)
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teries closely resembling its human counterpart. It appears
to be the best available model for the study of angioplasty
restenosis (107, 108).
The issue of which growth-promoting substances isolated
in tissue culture systems dominate in the in vivo situation
remains unresolved. The preceding studies suggest that
platelet-derived growth factor, low density lipoprotein and
a macrophage factor are important. Studies that alter these
factors in vivo will be needed to better focus clinical inter-
ventions designed to reduce restenosis.
Medical Approaches to Restenosis
Several interventions may reduce the rate of angioplasty
restenosis and these are considered here chiefly from the
standpoint of testable hypotheses that may be brought to
clinical trial. Data concerning some of these agents have
accumulated and will be discussed when appropriate.
Antiplatelet agents. The use of antiplatelet agents to
prevent restenosis is supported by experimental work (95)
demonstrating the growth promoting effects of platelets and
platelet-derived growth factor (95) and by clinical experi-
ence (109) using antiplatelet agents to prevent saphenous
vein bypass graft stenosis in the first year after coronary
artery bypass surgery, No controlled clinical trials of this
therapy versus placebo have been completed, although one
is currently underway. Most published series reporting re-
stenosis rates have employed antiplatelet therapy in some
if not all patients.
A variety of antiplatelet agents have been demonstrated
to diminish platelet adhesion to sites of experimental en-
dovascular injury (82), Aspirin plus dipyridamole given
before angioplasty may prevent thrombus formation in the
periangioplasty period in humans (110). Moreover, in the
rabbit model of experimental iliac atherosclerosis (96), an-
gioplasty resulted in restenosis in control animals which was
Figure S. Response to intraarterial
balloon injury in Macaca nemestrina
after 3 months (13) and6 months (14)
without cholesterol feeding. Several
layers of cells are present on the lu-
minal side of thedark, internal elastic
lamina 3 months after injury, butonly
oneto three layers after6 months, sug-
gesting an injury-mediated, reversi-
ble.proliferative response. (Reprinted
by copyright permission of the Rock-
efeller University Press from Stemer-
• man MB and Ross R /86).)
markedly attenuated in animals treated with aspirin plus
dipyridamole or with sulfinpyrazone.
Thornton et al. (30) reported a randomized trial of aspirin
versus warfarin (Coumadin) in 248 consecutive patients with
successful angioplasty. Subjects received either aspirin. 325
mg/day, or Coumadin to maintain a prothrombin time of 2
to 2.5 times control. Restenosis rates at 3 to 6 months after
angioplasty. measured angiographically. were 27% in the
aspirin group and 36% in the coumadin group. a difference
that was not statistically significant. These results suggest
that full anticoagulation with warfarin group drugs holds no
significant advantage over aspirin therapy alone in the pre-
vention of restenosis. The sample size was too small. how-
ever, to reliably detect even a 25% reduction in restenosis
rates. This study (30) did not address the broader question
of whether either therapy produced an advantage over no
antiplatelet or anticoagulant therapy. A randomized trial of
aspirin plus dipyridamole versus placebo in addition to short-
term heparin therapy in both groups is underway. This trial.
with anticipated completion in 1988. should answer the
latter question.
Lipid interventions. The Framingham Study ( III ) pro-
vided evidence of increased risk of coronary heart disease
from elevated total and low density lipoprotein cholesterol
and reduced high density lipoprotein cholesterol. Subse-
quent studies have tested whether cholesterol-lowering ther-
apy affects the development of coronary disease in patients
at risk. The Lipid Research Clinic Coronary Primary Pre-
vention Trial (112.113) provided evidence that reduction in
lipids in a high risk group exerted a dose-dependent pro-
tective effect from events due to coronary artery disease.
Additional studies (114-117) have evaluated the effects
of lipid-lowering interventions on the angiographic pro-
gression of coronary artery disease. The NHLBI Type 2A
Trial (118.119) found a small difference in the rate of an-
giographic progression of disease between cholestyramine-
and placebo-treated patients. Finally, the Leiden Interven-
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Figure 6, Scanning electron micro-
graphs after balloon injury in rabbits
without (top) andwith (bottom) 0.1%
cholesterol feeding. In both micro-
graphs the injured segment occupies
the left half of the field. Animals fed
with cholesterol showed enhancement
of leukocyte attachment to regenerat-
ing endothelium after balloon injury.
(Reprinted with permission of the
American Heart Association Inc. from
Walker LN and Bowyer DE [105).)
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tion Trial (120) suggested that a strict vegetarian diet de-
creased the ratio of total to high density lipoprotein cho-
lesterol closer to a threshold below which progression is
unlikely to occur.
Skepticism about the biologic significance ofcholesterol-
lowering therapy is widespread. however (121,122) . In-
ability to find differences in all-cause mortality with treat-
ment and failure to describe the effects of lipid-lowering
therapy on the rate of progression of insignificant to sig-
nificant lesions (that is. 50 to 75% diameter stenosis) are
among the problems (122).
Both sets of objections can be addressed in angioplasty
restenosis trials. The shorter term of follow-up and primary
angiographic end point at a single site on the arteriogram
would simplify the interpretation of lipid-lowering inter-
ventions in patients undergoing angioplasty. Lesions after
angioplasty appear to undergo more measurable changes
when compared with chronic atheroma. For example, in
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addition to the occurrence of postangioplasty restenosis there
is evidence that up to one-third of patients have spontaneous
increases in angiographic vessel diameter or area (67.1 23).
In contrast, regression of chronic atherosclerosis is docu-
mented in animal models (87.90. 124) but is only tenuously
supported by studies in humans ( I 14-121 ).
Thus far two preliminary reports have suggested that
hypercholesterolemia or hyperl ipidemia is associated with
restenosis (62.68). These studies require confirmation. Given
experimental data suggesting that lipids and growth factors
promote smooth muscle cell proliferation in response to
injury, the suggested impact of lipid-lowering interventions
on patients with type IIa hyperlipidemia and the preliminary
report of an association between hypercholesterolemia and
restenosis, it is reasonable to suggest that lipid interventions
be conducted on a trial basis in patients undergoing angio-
plasty.
Diabetes mellitus. Preliminary reports (35.62.66) have
suggested that patients with diabetes have a greater risk for
restenosis after angioplasty. No studies have related the
type, severity or level of glycemic control in diabetes. mea-
sured by glucosylated hemoglobin. levels of low density
lipoprotein cholesterol, apolipoprotein B and triglyceride or
intensification of diabetic treatment with restenosis ( 125).
Markers such as glucosylated hemoglobin could serve as a
tool for analysis of the relation of restenosis to glycemic
control (126,127). Restenosis rates and degree could be
correlated with level of glycemic control and trials in which
intensification of diabetic treatment to lower glucosylated
hemoglobin levels could be designed to assess the impact
of such therapy on rates of restenosis.
Calcium channel antagonists. Calcium antagonist drugs
have been demonstrated to retard the development of ath-
erosclerosis in cholesterol-fed animal models (128.129). al-
though this action has not been confirmed in the single
example of the Watanabe hereditary hyperlipidemic rabbit
(130). Furthermore, nifedipine failed to protect animals from
restenosis in the same rabbit angioplasty preparation in which
antiplatelet agents were successful ( 131). These agents have
the potential to prevent injury-associated coronary spasm
both in the immediate and late periods after angioplasty.
and have salutary effects on symptoms produced by he-
modynamically significantcoronary artery disease (77 .132).
Two studies (32.133) failed to show significant differ-
ences in restenosis rates at the time of repeat angiography
6 to 8 months after initial angioplasty in patients receiving
nifedipine or diltiazem versus placebo. Neither of these
studies had adequate sample size to detect a 25% reduction
in restenosis rates. Hollman et al . ( 132) identified 5 patients
of I ,000 who developed angina at rest within 2 months after
angioplasty. In these five patients a maximal fixed stenosis
2 months after angioplasty was 30%. but two patients dem-
onstrated spontaneous coronary spasm during angiography
and three had spasm provoked with ergonovine. Three of
these fi ve patients developed rapidly progressive exertional
angina and a > 75% lesion at the angioplasty site. suggesting
that coronary spasm predisposed this group to a greater
incidence of restenosis at the site of angioplasty. The small
size of the patient sample makes any conclusion on the basis
of this study preliminary. Despite their theoretical attrac-
tiveness. calcium antagonists have not shown significant
benefit with regard to restenosis after angioplasty in pub-
lished trials.
Timing, Design and Sample Size
Timing. To have an impact on growth factors interacting
with endothelial cells, smooth muscle cells and formed blood
cell elements. therapy designed to favorably affect reste-
nosis would ideally be initiated before the date of elective
angioplasty, but how long in advance? Platelet function can
be quickly altered by cyclooxygenase inhibitors or within
hours to days by phosphodiesterase inhibitors (82, 131.
133-1 35). Fish-oil concentrates alter the function of leu-
kocytes within 6 weeks and platelet function in I to 2 weeks
( 136- 138). Drugs such as cholestyramine usually produce
significant decreases in serum cholesterol within I to 2 weeks
(139). In order to conform to current modes of practice in
which many patients have angioplasty within a few days of
diagnostic catheterization. insisting on preangioplasty ther-
apy for longer than a few days to a week may not be prac-
tical. Because of the increased risk of restenosis during the
fi rst 6 months after angiopla sty, treatment should continue
at least 6 to 12 months. using repeat angiography as the
standard for assessing restenosis end points. Animal ex-
periments ( 140) have suggested that healing and reendothe-
lialization may take up to 9 months where large areas of
injury have been created.
Design. The natural history of the angioplasty site and
risk factors for restenosis should be further evaluated in
untreated groups. The impact of smoking, blood pressure.
hyperglycemia. hyperlipidemia. exercise frequency. body
weight and personality type could all be rigorously scruti-
nized before and in the 6 months after angioplasty when an
injury-mediated acceleration of the occlusive process ap-
pears to occur. As has been done in the past. patients with
multivessel restenosis can be compared with patients with
single vessel restenosis after multivessel angioplasty in the
search for prospectively collected variables that suggest sys-
temic versus local factors.
Specific drug or dietary therapy should be selected to
permit double blinding and randomizing. Compliance should
be greater than for long-term studies. because patients can
be counseled that such therapy is only temporary. Rigorous
attention to documentation of compliance should be main-
tained.
Design 01' trials 01' alternative antiplatelet regimens is
hampered by the unproved status of what has become stand-
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ard therapy: aspirin or aspirin plus dipyridamole . Heparin,
which may promote lysis of coronary thrombi in unstable
chest pain syndromes (141), is usually used in conjunction
with the preceding agents. Until the trial of short-term hep-
arin plus I year of aspirin and dipyridamole is completed
in 1988. trials should probably compare new therapies with
either the above regimen or with placebo. 11 is important to
note that the restenosis rate in the absence of antiplatelet
therapy with or without heparin is unknown.
Design problemsfor lipid-lo wering interventions include
threshold target levels of serum lipids, choices of diet alone
or diet plus drug and choices of appropriate drugs. Inter-
ventions that have induced regression of disease in exper-
imental animals have, in general. identified a threshold in
the range of 180mg/dl for total serum cholesterol (87,90,123).
The Leiden Intervention Trial (120) suggested that a total
cholesterol to high density lipoprotein ratio of 2:6.9 was
associated with no measurable angiographic progression of
coronary disease. Because 50% of American men in their
50s and 60s have total serum cholesterol levels >200 mg/dl
(142), it may be appropriate to randomize most if not all
patients undergoing angioplasty to diet plus drug or no ther-
apy. As an alternate strategy , diet alone could be selected
on the basis of a borderline cholesterol value. In a clinical
trial we favor maximal therapy (diet plus drug plus exercise)
for all patients with total cholesterol > 250 mg/dl. Mea-
surements of total serum cholesterol, high density lipopro-
tein cholesterol and total triglycerides, allowing calculated
levels of low density lipoprotein cholesterol, should be fol-
lowed. Measuring apoprote in fractions is of uncertain clin-
ical benefit but may provide useful pathophysiologic insight
in a clinical trial. Outcome could , of course, be assessed
with regard to the magnitude of directional change of the
serum lipid profile.
In subjects with elevated glucosylated hemoglobin. trials
of intensive versus conventional diabetic care may be war-
ranted.
Future trials of calcium antagonists should probably be
limited to patients with suspected coronary spasm, whose
number at any one institution is apt to be small. The question
of benefit of calcium antagonist therapy might best be an-
swered in a randomized multicenter placebo-controlled trial
in which identification of variant angina, magnitude and
duration of therapy and uniformity of interval for follow-
up can be standardized.
Sample size. If the risk of restenosis in a placebo-treated
population is 30%, large sample sizes will be needed to
detect a significant effect of an intervention. For example,
if a therapy reduces the risk of restenosis from 30% to 22.5%
(a 25% reduction), 596 patients will be needed to have an
80% chance of detecting this difference . With a slightly
more potent intervention that lowered the restenosis rate to
20% (a 33% reduction), 320 patients would be required to
achieve the same power. These calculations are based on
the measurement of restenosis as a binary outcome . The
quantification of the coronary lesions with digital angiog-
raphy and videodensitometry would allow for the measure-
ment of the angiographic end point in a continuous fashion.
Evaluating the effect of an intervention on percent area
narrowing or videodensitometric density as a continuous
function would markedly lower the sample size needed.
Conclusions
At this time angioplasty is the only widely accepted avail-
able means of achieving coronary revascularization without
surgery. The number of patients undergoing angioplasty in
the United States in 1985 approximated 50,000 to 90,000
(\43,144), one-third of whom will reasonably be expected
to have restenosis within the first 6 months after the pro-
cedure. The difference in cost between successful angio-
plasty and failed angioplasty with operative treatment for
restenosis has been estimated as $12,528 per patient (145).
The increased morbidity and mortality of subjecting patients
to two procedures instead of one is a further consideration .
New techniques of nonoperative revascularizat ion are not
expected to be widely available within the next 5 years. In
the immediate future the use of angioplasty will probably
increase, resulting in a greater number of patients returning
with restenosis.
Preventive therapy. Definitive recommendations for a
clinical approach to the prevention of restenosis must await
the completion of clinical trials. Nevertheless, physicians
must use currently available information to devise strategies
as they face the clinical challenge of preventing restenosis ,
We suggest that current therapy for elective angioplasty
focus on two objectives; first, the prevention of acute mac-
roscopic thrombus formation at the site of angioplasty and,
second, the reduction of smooth muscle cell proliferation .
We recommend that aspirin, 325 mg three times/day, and
dipyridamole, 75 to 100 mg three to four times/day, be
initiated 24 to 48 hours prior to angioplasty and be continued
for 6 months. Heparin infusion may be used in patients with
complex technically difficult lesions requiring a lengthy pro-
cedure and may be continued for 2 days after the procedure .
Nitroglycerin or calcium antagonist therapy to prevent acute
injury-related coronary spasm would be considered optional
during this period.
Risk factor modification. Additional interventions to
modify risk factors associated with the development of ath-
erosclerosis may provide the patient with a unique oppor-
tunity to alter the course of the disease . Particular emphasis
should be placed on the control of diabetes and smoking
cessation. A low fat, low cholesterol diet should be strictly
followed by all postangioplasty patients and drug therapy
to reduce. cholesterol should be considered in patients with
total serum cholesterol > 275 mg/dl. We consider a struc-
tured exercise program to be an essential component of a
lACC Vol. 9. No.4
April 19X7:X34-48
BI.ACKSHEAR ET AL.
MEDICAL APPROACHES TO RESTENOSIS
845
restenosis prevention program because of its beneficial ef-
fects on lipids, fibrinolytic activity and smoking cessation
as well as providing a systematic approach to the control
of hypertension, diabetes and the earl y detection of recurrent
symptoms related to restenosis.
Clinical trials. Attractive medical approaches to the
problem of restenosis can be applied through study popu-
lations in a manner that should yield useful clinical data.
The study of restenosis in patients who have had coronary
angioplasty has several advantages over the study of ath-
erosclerosis in patients who have not had angioplasty. The
study of restenosis provides the opportunity to intervene
during the apparent accelerated evolution of atherosclerosis
in which cells involved in the production of stenosis are
actively proliferating or regressing. Problems in interpreting
an entire coronary arteriogram are replaced by the ability
to focus on a single angioplasty site using objective measures
to quantify changes from baseline to follow-up studies.
Dropout rates due to side effects, death from other causes
or noncompliance should be minimized by the 6 to 12 month
term of study.
The experimental evidence reviewed provides a rationale
for the use of aggressive antirestenosis therapy to be initiated
before angioplasty and continued intensively for 6 months
to a year after the procedure. Success achieved in medical
approaches to restenosis would greatly improve the long-
term outlook for coronary angioplasty and future mechanical
techniques for coronary revascularization.
We gratefully acknowledge the assistance of Richard S. Stack. MD. Di-
rector of the lnterventional Cardiac Catheterization Laboratory at Duke
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